Empowering ophthalmologists with AI-based therapy assistants to provide patient-specific retinal treatments, achieving optimal vision outcomes.
is caused by retinal diseases - and thus preventable.
Source : WHO World Vision Report 2019
globally suffer from vision-threatening retinal diseases, requiring lifelong and regular treatments.
Source : WHO World Vision Report 2019
is affected by Age-related Macular Degeneration (AMD), one of the leading causes of blindness
Source : WHO/Resnikoff
To optimize your patients' IVT treatment and save time, benefit from an AI-based assistant that supports you like a second expert opinion with powerful key indicators.
More than just data, deepeye delivers actionable insights, aiding in robust treatment planning that overcome the limitations of conventional treatment regimen like T&E, PRN, IVAN, and CATT. Our pursuit of algorithmic refinement aims to redefine the treatment narrative for retinal diseases towards a (patient) need-based "predict & treat" (P&T).
Our flexible AI platform elevates the capabilities of retinal therapy study teams, serving pharmaceutical companies, medical device manufacturers and payors with unparalleled efficiency and insight.
We develop 1-click predictive AI solutions for personalised treatment.
They are based on a proven clinical method using expert 2nd opinion to achieve up to:
3x better results
2x therapy persistence
over 24 months and 2'466 patients compared to standard-of-care.
We analyze retinal therapy datasets for new insights. Our approach takes the proven approach of one of the leading reading and study centers in the EU, involved in all major phase III+IV trials for anti-VEGF agents in the last years to the next level.
.gif)
Based on tens of thousands of similar cases, treated with exceptional results.
Provides actual disease activity & Biomarkers vizualisation.
Prediction of expected treatment need over the coming 12 months.
1 click generated AI reports, works with all major retinal imaging systems.
